Unknown

Dataset Information

0

Adjuvant sorafenib for liver cancer: wrong stage, wrong dose.

ABSTRACT:

SUBMITTER: Kelley RK 

PROVIDER: S-EPMC4811670 | biostudies-literature |

REPOSITORIES: biostudies-literature

Json Xml

Similar Datasets

Unknown Adjuvant sorafenib after heptectomy for Barcelona Clinic Liver Cancer-stage C hepatocellular carcinoma patients.
| S-EPMC4910659 | biostudies-literature
Unknown Recombinant human acid sphingomyelinase as an adjuvant to sorafenib treatment of experimental liver cancer.
| S-EPMC3665770 | biostudies-literature
Unknown Early discontinuation and dose reduction of adjuvant chemotherapy in stage III colon cancer patients.
| S-EPMC8072866 | biostudies-literature
Unknown A comparative study of sorafenib and metronomic chemotherapy for Barcelona Clinic Liver Cancer-stage C hepatocellular carcinoma with poor liver function.
| S-EPMC5497665 | biostudies-literature
Unknown Adjuvant Sorafenib Following Radiofrequency Ablation for Early-Stage Recurrent Hepatocellular Carcinoma With Microvascular Invasion at the Initial Hepatectomy.
| S-EPMC9260661 | biostudies-literature
Unknown Label-retaining liver cancer cells are relatively resistant to sorafenib.
| S-EPMC6993136 | biostudies-literature
Unknown Artesunate and sorafenib: Combinatorial inhibition of liver cancer cell growth.
| S-EPMC6781774 | biostudies-literature
Unknown Adjuvant platinum-based chemotherapy for early stage cervical cancer.
| S-EPMC4164460 | biostudies-literature
Unknown Duration of Adjuvant Chemotherapy for Stage III Colon Cancer.
| S-EPMC6426127 | biostudies-literature
Unknown New knowledge of the mechanisms of sorafenib resistance in liver cancer.
| S-EPMC5457690 | biostudies-literature